Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?
- 1 February 2001
- journal article
- review article
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 3 (1) , 30-37
- https://doi.org/10.1007/s11894-001-0038-z
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Evaluation of the safety and efficacy of once-weekly PEG/interferon alfa-2A (PEGASYS™) for chronic hepatitis C. A multinational, randomized studyJournal of Hepatology, 2000
- Pegylated interferon alfa-2B (PEG-intron) mono-therapy is superior to interferon alfa-2B (intron A) for the treatment of chronic hepatitis CJournal of Hepatology, 2000
- Influence of Human Serum Albumin Content in Formulations on the Bioequivalency of Interferon Alfa‐2a Given by Subcutaneous Injection in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1995
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced MyelosuppressionNew England Journal of Medicine, 1988
- Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene glycol-modified adenosine deaminaseThe Journal of Pediatrics, 1988
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987
- Effects of Polyethylene Glycol Substitution on Enzyme ActivityJournal of Bioactive and Compatible Polymers, 1987
- Modification of human hemoglobin with polyethylene glycol: A new candidate for blood substituteBiochemical and Biophysical Research Communications, 1980
- Modification of E. coli L-asparaginase with polyethylene glycol: Disappearance of binding ability to anti-asparaginase serumBiochemical and Biophysical Research Communications, 1978